RxDoctor Payments Data

Ashley Six, PA

Physician Assistant · Houston, TXNPI 1912598483

Payments from drug & device makers

$16,102in general payments, 2019–2025

Across 638 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Novartis$1K
  • Merck$1K
  • E.r. Squibb & Sons, L.L.C.$970
  • AstraZeneca$789
  • Lilly USA, LLC$700
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$15,05393%
  • Education$1,0497%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson46$1,586
Novartis68$1,317
Merck50$1,129
E.r. Squibb & Sons, L.L.C.42$970
AstraZeneca(2 entities)27$789
Lilly USA, LLC25$700
Rigel Pharmaceuticals, Inc.20$558
Incyte Corporation18$520
Seagen Inc.17$511
Pfizer20$482
AbbVie15$447
Amgen19$418
Sanofi17$399
Daiichi Sankyo Inc.17$387
Bayer14$326
GSK15$320
Bristol Myers Squibb12$272
Pharmacyclics LLC, An Abbvie Company10$264
Regeneron Healthcare Solutions, Inc.9$254
Takeda Pharmaceuticals U.S.A., Inc.10$243
Beigene USA, Inc.2$234
Deciphera Pharmaceuticals Inc.9$222
Sanofi-aventis U.S. LLC2$200
AVEO Pharmaceuticals, Inc.7$183
Sobi, Inc6$179
Ipsen Biopharmaceuticals, Inc8$177
Karyopharm Therapeutics Inc.9$175
Myriad Genetic Laboratories, Inc.3$174
Taiho Oncology, Inc.8$170
ADC Therapeutics America, Inc.2$145
Eisai Inc.7$140
Astellas Pharma US Inc7$120
Tersera Therapeutics LLC4$103
Exelixis Inc.6$103
Genentech USA, Inc.4$86
Pharmaessentia USA Corporation3$84
Stemline Therapeutics Inc.4$81
Alnylam Pharmaceuticals Inc.3$80
Adaptive Biotechnologies Corporation3$78
Springworks Therapeutics, Inc.3$78
Puma Biotechnology, Inc.3$73
EMD Serono, Inc.4$71
Genmab U.S., Inc.3$67
Mirati Therapeutics, Inc.4$65
Blueprint Medicines Corporation3$63
Array Biopharma Inc3$60
Gilead(2 entities)3$57
Geron Corporation2$56
Pharmacosmos Therapeutics Inc.2$56
Servier Pharmaceuticals LLC3$54
CTI Biopharma Corp.2$53
Myovant Sciences Inc.2$52
Amneal Pharmaceuticals LLC2$47
Mylan Institutional Inc.2$43
Spectrum Pharmaceuticals Inc.2$42
Coherus Oncology, Inc.2$41
Morphosys, US Inc.2$40
Epizyme, Inc.2$39
Agios Pharmaceuticals, Inc.1$36
Dova Pharmaceuticals2$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,102 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$5,158
Medicare patients
42
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VerzenioAbemaciclib40$607,664
BrukinsaZanubrutinib33$385,635
JakafiRuxolitinib Phosphate11$181,744
XtandiEnzalutamide17$149,026
Sunitinib Malate17$135,314
InlytaAxitinib11$124,771
EliquisApixaban56$54,843
Abiraterone Acetate18$30,922
XareltoRivaroxaban24$16,151
Letrozole66$1,400
Famciclovir16$1,118
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine39$501
Dexamethasone20$481
Hydroxyurea18$468
Gabapentin35$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCVerzenio$700$607,66440 claims
Beigene USA, Inc.Brukinsa$234$385,63533 claims
Incyte CorporationJakafi$520$181,74411 claims
PfizerInlyta, Eliquis$482$179,61567 claims
Astellas Pharma US IncXtandi$120$149,02617 claims
Johnson & JohnsonXarelto$1,586$16,15124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →